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RESULTS: By the end of the ﬁrst year, Tacrolimus
increases the number of ‘disease controlled days’ with 59
days at an IC of €60, implying an ICER of 1€/disease con-
trolled day. Better ICERs are obtained in severe AD, when
taking into account UV light therapy costs in the steroid
arm, currently not reimbursed in Belgium. Due to the long
term clinical improvement, the ICER decreases with treat-
ment duration and Tacrolimus ointment is estimated to
become cost-saving as from 2 years treatment duration.
CONCLUSION: Tacrolimus is a cost-effective treatment
for moderate to severe AD, providing potential savings to 
the health care system during long term maintenance
treatment.
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OBJECTIVES: To evaluate the cost and utility of cal-
cipotriol/bethamethasone (Dovobet) compared to cal-
cipotriol (Dovonex) in the treatment of psoriasis vulgaris.
METHODS: A four-state Markov model was designed to
estimate the cost and utilities associated with psoriasis
treatment over a full year. The model consists of four
mutually exclusive health states: Controlled psoriasis, and
three states of uncontrolled psoriasis: Initial treatment,
subsequent treatment, and no treatment. Various sources
were used to estimate the parameters of the model, but
the primary source for utility scores and transition prob-
abilities was an international phase III trial, estimating
efﬁcacy and the quality of life for 737 patients ran-
domised to one of four different treatment options.
Among the treatment options were calcipotriol/
bethamethasone (Dovobet) once daily and the currently
most frequently prescribed topical antipsoriatic in the
UK, calcipotriol (Dovonex). RESULTS: In the baseline
model, the average annual cost to the NHS associated
with treatment of a psoriasis patient with calcipotriol/
bethamethasone (Dovobet) once daily amounted to
£64.7. The cost of calcipotriol twice-daily treatment in
the same period would amount to £120.3. In terms 
of number of QALYs gained in a year, calcipotriol/
bethamethasone (Dovobet) once daily patients on average
accumulated 0.7719 QALYs, compared to calcipotriol
twice daily patients who accumulated only 0.7599
QALYs. Thus, in the baseline model treatment with cal-
cipotriol/bethamethasone (Dovobet) twice daily is both
less costly and more effective than the current standard
therapy of calcipotriol twice daily. These results were
robust to extensive sensitivity analysis of important
assumptions. CONCLUSION: Looking at a full year of
treatment, the cost-utility analysis showed that cal-
cipotriol/bethamethasone (Dovobet) once daily was both
less expensive and yielded more QALYs than the current
standard therapy (calcipotriol).
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Atopic dermatitis is considered in modern society to be a
disease leading to large expenses of the state, person and
family. OBJECTIVE: Pharmacoeconomic analysis of
family expenses and losses connected with child’s atopic
dermatitis. METHODS: cost and expenses analysis of the
disease was conducted with account of expenses on phar-
macotherapy, hospital and ambulance treatment, disable-
ment pensions, temporary disability of parents and
evaluation of the disease inﬂuence on the standard of life
of the child and the whole family. In 2000–2003 we have
conducted polling of families with children having atopic
dermatitis, analysis of ambulatory cards and case histo-
ries in Vladivostok Children’s Municipal Clinic Hospital.
Also, life standard questionnaires were ﬁlled in.
RESULTS: Family expenses on the child’s disease treat-
ment in 2000 were 9658.9 rubles ($311.5), in 2001—
12142.1 rubles ($379), in 2002—13400 rubles ($446),
which made from 9.6 to 13.4% of family annual income.
The largest speciﬁc weight of expenses (36.1%) was
shown by drugs purchase: in 2000—3486.8 rubles
($112), in 2001—4383.2 ($136), 2002—4837.4 rubles
($161). In 2000 atopic dermatitis caused hospitalization
of the child in average in 1.54 ± 0.2 cases in a year, period
of treatment 15.62 ± 1.02 days. In 2002 share of expenses
on basis antiinﬂammatory therapy and consultations 
of allergist and dermatologist increased, while number of
hospitalization cases reduced to 1.01 ± 0.1, duration of
hospitalization reduced down to 10.37 ± 0.94 days per
one child in average during a year. Atopic dermatitis
detected decrease in life quality not only of the child but
also of the family as a whole. CONCLUSIONS: Effective
pharmacotherapy and observance of hypoallergic every
day life regulations led to improvement of children life
quality, reduced expenses on hospital assistance, tempo-
rary disability and disablement but increased the burden
of family expenses on drugs.
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